Table 1.
PRO Compliance Multivariate Analysis Institutions that Enrolled to Both Studies
| Odds Ratio | 95% Confidence | Interval p-value | |
|---|---|---|---|
| A) Prostate - EQ-5D | |||
| Intercept | 17.44 | −1.32,1.07 | 0.83 |
| Time=1 Year (6 months) | 0.34 | −1.40,−0.78 | <0.001 |
| Time=5 Years (6 months) | 0.41 | −1.18,−0.60 | <0.001 |
| Age (≤ 65) | 0.69 | −0.68,−0.06 | 0.020 |
| Zubrod (0) | 1.56 | −0.01,0.89 | 0.053 |
| Race (White) | 1.30 | −0.08,0.60 | 0.13 |
| Baseline PSA = 10–20 ( < 10) | 0.94 | −0.63,0.51 | 0.84 |
| Baseline PSA = > 20 ( <10) | 1.40 | −0.25,0.93 | 0.26 |
| T-Stage (T1) | 1.13 | −0.19,0.44 | 0.44 |
| Study (NRG/RTOG 0815) | 0.630 | 0.45, 0.88 | 0.006 |
| B) Prostate - PROMIS | |||
| Intercept | 1.59 | 0.49, 5.18 | 0.44 |
| Time=1 Year (6 months) | 4.09 | 2.93, 5.705 | <0.001 |
| Time=5 Years (6 months) | 3.09 | 2.30, 4.15 | <0.001 |
| Age (≤ 65) | 1.44 | 1.05, 1.98 | 0.024 |
| Zubrod (0) | 0.62 | 0.38, 0.99 | 0.048 |
| Race (White) | 0.76 | 0.54, 1.07 | 0.12 |
| Baseline PSA = 10–20 ( < 10) | 0.96 | 0.54, 1.69 | 0.88 |
| Baseline PSA = > 20 ( <10) | 0.76 | 0.42, 1.40 | 0.38 |
| T-Stage (T1) | 0.90 | 0.65, 1.23 | 0.50 |
| Study (NRG/RTOG 0815) | 1.33 | 0.94, 1.86 | 0.10 |
| C) Prostate – PSQI/GLTEQ | |||
| Intercept | 1.84 | 0.59, 5.72 | 0.30 |
| Time=1 Year (6 months) | 3.84 | 2.73, 5.38 | <0.001 |
| Time=5 Years (6 months) | 2.55 | 190, 3.43 | <0.001 |
| Age (≤ 65) | 1.45 | 1.07, 1.98 | 0.018 |
| Zubrod (0) | 0.72 | 0.43, 1.19 | 0.20 |
| Race (White) | 0.73 | 0.52, 1.01 | 0.057 |
| Baseline PSA = 10–20 ( < 10) | 0.93 | 0.52, 1.64 | 0.80 |
| Baseline PSA = > 20 ( <10) | 0.78 | 0.43, 1.43 | 0.42 |
| T-Stage (T1) | 0.86 | 0.63, 1.18 | 0.36 |
| Study (NRG/RTOG 0815) | 1.32 | 0.94, 1.84 | 0.11 |
| D) Cosmesis | |||
| Intercept | 5.52 | 2.95, 10.33 | <0.001 |
| Time=12 months (6 months) | 1.00 | 0.60, 1.69 | 0.99 |
| Time=24 months (6 months) | 0.65 | 0.35, 1.21 | 0.17 |
| Time=36 months (6 months) | 0.41 | 0.24, 0.71 | 0.0014 |
| Age (≤ 60) | 0.67 | 0.36, 1.28 | 0.81 |
| Race (White) | 1.07 | 0.59, 1.96 | 0.62 |
| Stage (0/I) | 1.30 | 0.47, 3.63 | 0.14 |
| Study (RTOG 1005) | 0.63 | 0.34, 1.17 | 0.23 |
Modeling the probability that form completion=Yes (n=1295/1582 for EQ-5D, n=1386/1644for PROMIS, n=1350/1612 for PSQI/GLTEQ, n=378/500 for Cosmesis). Reference Category is specified in brackets (). PRO=Patient-reported outcome; PROMIS=Patient-Reported Outcomes Measurement Information System; PSQI=Pittsburgh Sleep Quality Index; GLTEQ = Godin Leisure-Time Exercise Questionnaire.